GZMA | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	46 studies	76% ± 20%	Explore
CD8-positive, alpha-beta T cell	39 studies	58% ± 25%	Explore
T cell	27 studies	42% ± 19%	Explore
mature NK T cell	22 studies	74% ± 16%	Explore
CD4-positive, alpha-beta T cell	21 studies	35% ± 17%	Explore
gamma-delta T cell	20 studies	56% ± 23%	Explore
CD16-negative, CD56-bright natural killer cell, human	18 studies	69% ± 19%	Explore
mucosal invariant T cell	17 studies	65% ± 22%	Explore
CD16-positive, CD56-dim natural killer cell, human	17 studies	82% ± 18%	Explore
effector memory CD8-positive, alpha-beta T cell	12 studies	59% ± 27%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	58% ± 16%	Explore
effector CD8-positive, alpha-beta T cell	9 studies	73% ± 24%	Explore
CD4-positive, alpha-beta memory T cell	9 studies	31% ± 15%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	7 studies	46% ± 17%	Explore
CD4-positive, alpha-beta cytotoxic T cell	6 studies	58% ± 25%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	6 studies	65% ± 24%	Explore
innate lymphoid cell	5 studies	60% ± 25%	Explore
exhausted T cell	5 studies	86% ± 12%	Explore
effector CD4-positive, alpha-beta T cell	5 studies	47% ± 18%	Explore
central memory CD8-positive, alpha-beta T cell	4 studies	47% ± 23%	Explore
leukocyte	4 studies	34% ± 13%	Explore
CD4-positive helper T cell	4 studies	21% ± 4%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	34% ± 16%	Explore
T-helper 17 cell	4 studies	29% ± 11%	Explore
lymphocyte	3 studies	41% ± 17%	Explore
T-helper 1 cell	3 studies	41% ± 10%	Explore
double negative thymocyte	3 studies	60% ± 14%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	19 studies	25% ± 6%	Explore
lung	4 studies	22% ± 5%	Explore
liver	4 studies	33% ± 16%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	399.83	578 / 578	90%	39.82	1043 / 1155
stomach	90%	111.93	324 / 359	73%	24.46	210 / 286
uterus	83%	83.14	141 / 170	77%	58.41	355 / 459
breast	78%	83.97	359 / 459	75%	26.05	839 / 1118
liver	90%	103.96	203 / 226	53%	14.52	215 / 406
thymus	80%	114.47	524 / 653	62%	18.87	373 / 605
intestine	68%	171.75	659 / 966	73%	22.86	385 / 527
kidney	55%	70.72	49 / 89	80%	45.66	718 / 901
bladder	67%	100.52	14 / 21	62%	24.38	314 / 504
prostate	78%	77.38	190 / 245	51%	8.14	254 / 502
esophagus	53%	45.75	766 / 1445	57%	14.98	104 / 183
pancreas	20%	11.77	65 / 328	81%	23.72	144 / 178
lymph node	0%	0	0 / 0	100%	207.24	29 / 29
spleen	100%	1677.29	241 / 241	0%	0	0 / 0
adipose	93%	152.43	1125 / 1204	0%	0	0 / 0
tonsil	0%	0	0 / 0	89%	70.23	40 / 45
skin	18%	11.14	329 / 1809	68%	38.26	321 / 472
peripheral blood	84%	1600.14	782 / 929	0%	0	0 / 0
ovary	31%	26.16	55 / 180	52%	9.69	222 / 430
adrenal gland	52%	38.06	135 / 258	20%	3.42	45 / 230
blood vessel	56%	73.01	750 / 1335	0%	0	0 / 0
heart	37%	24.53	322 / 861	0%	0	0 / 0
brain	12%	8.11	330 / 2642	16%	2.90	110 / 705
eye	0%	0	0 / 0	21%	7.27	17 / 80
muscle	8%	4.84	68 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0140507	Biological process	granzyme-mediated programmed cell death signaling pathway
GO_0009617	Biological process	response to bacterium
GO_0070269	Biological process	pyroptotic inflammatory response
GO_1902483	Biological process	cytotoxic T cell pyroptotic cell death
GO_0006955	Biological process	immune response
GO_0051354	Biological process	negative regulation of oxidoreductase activity
GO_0031640	Biological process	killing of cells of another organism
GO_0032078	Biological process	negative regulation of endodeoxyribonuclease activity
GO_0043392	Biological process	negative regulation of DNA binding
GO_0006915	Biological process	apoptotic process
GO_0051603	Biological process	proteolysis involved in protein catabolic process
GO_0043065	Biological process	positive regulation of apoptotic process
GO_0051604	Biological process	protein maturation
GO_0001772	Cellular component	immunological synapse
GO_0005615	Cellular component	extracellular space
GO_0005737	Cellular component	cytoplasm
GO_0005634	Cellular component	nucleus
GO_0042803	Molecular function	protein homodimerization activity
GO_0005515	Molecular function	protein binding
GO_0004252	Molecular function	serine-type endopeptidase activity

IV. Literature review

[source]

Gene name	GZMA
Protein name	Granzyme A (EC 3.4.21.78) (CTL tryptase) (Cytotoxic T-lymphocyte proteinase 1) (Fragmentin-1) (Granzyme-1) (Hanukkah factor) (H factor) (HF)
Synonyms	CTLA3 HFSP
Description	FUNCTION: Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse . It cleaves after Lys or Arg . Once delivered into the target cell, acts by catalyzing cleavage of gasdermin-B (GSDMB), releasing the pore-forming moiety of GSDMB, thereby triggering pyroptosis and target cell death . Cleaves APEX1 after 'Lys-31' and destroys its oxidative repair activity . Cleaves the nucleosome assembly protein SET after 'Lys-189', which disrupts its nucleosome assembly activity and allows the SET complex to translocate into the nucleus to nick and degrade the DNA . .
Accessions	P12544 ENST00000274306.7 [P12544-1]

GZMA report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review